The Patent Finder

Terms ending in 2037

Eyepoint, Inc.

Every in-force patent on Eyepoint, Inc.'s record whose computed term ends in 2037, whoever holds it now. Soonest term end first, then patent number.
PatentTitleHolderStatusExpiresConfidence
US 10,253,094Antibodies That Target Human Protein Tyrosine Phosphatase-Beta (HPTP-BETA) and Methods of Use Thereof to Treat Ocular Conditions
In force
 · High confidence
Eyepoint, Inc.In forceHigh confidence
US 10,597,452Methods of Treating Ocular Conditions by Administering Humanized Monoclonal Antibodies That Target Ve-Ptp (HPTP-BETA)
In force
 · High confidence
Eyepoint, Inc.In forceHigh confidence
US 10,604,569Humanized Monoclonal Antibodies That Target Protein Tyrosine Phosphatase-Beta (Hptp-Beta / Ve-Ptp)
In force
 · High confidence
Eyepoint, Inc.In forceHigh confidence
US 11,136,389Humanized Monoclonal Antibodies That Target Ve-Ptp (HPTP-BETA)
In force
 · High confidence
Eyepoint, Inc.In forceHigh confidence
US 11,180,551Humanized Monoclonal Antibodies That Target Ve-Ptp (HPTP-Beta)
In force
 · High confidence
Eyepoint, Inc.In forceHigh confidence
US 12,145,986A Method of Treating an Ocular Condition by Administering a Humanized Monoclonal Antibodies That Target Ve-Ptp (HPTP-Beta)
In force
 · Medium confidence
Eyepoint, Inc.In forceMedium confidence
6 of 6 patents shown. Soonest term end first, then patent number.
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited